14 patents
Utility
Compositions and Methods for Treating Blood Disorders
7 Dec 23
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA)), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, paroxysmal cold hemoglobinuria (PCH), antiphospholipid syndrome (APS), Evans syndrome, red blood cell alloimmunization, Felty's syndrome, neonatal alloimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombosis, vasculitis, lupus nephritis, systemic lupus erythematosus (SLE), glomerulonephritis, anti-phospholipid antibody syndrome (APS), an infection, or a drug-induced hematologic disorder), comprising administering to a subject an inhibitor of the complement pathway.
Ted Yednock, Sethu Sankaranarayanan
Filed: 15 Oct 21
Utility
Inhibitors of complement factors and uses thereof
14 Nov 23
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof.
Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Federico Sorana, Bruno Di Guglielmo, Chiara Padroni
Filed: 19 Jul 21
Utility
Anti-complement Factor C1Q Antibodies with Single Binding Arms and Uses Thereof
7 Sep 23
The present disclosure relates generally to antibodies with a single antigen-binding arm comprising a single antigen-binding arm and an Fc region such as a single-arm antibodies.
Ted Yednock, Sethu Sankaranarayanan
Filed: 13 Dec 22
Utility
Anti-complement factor C1Q antibodies and uses thereof
16 May 23
The present invention provides anti-C1q antibodies and methods of using the same.
Arnon Rosenthal, Michael Leviten
Filed: 10 Feb 21
Utility
Inhibitors of Complement Factors and Uses Thereof
17 Feb 22
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof.
Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Frederico Sorana, Bruno Di Guglielmo, Chiara Padroni
Filed: 19 Jul 21
Utility
Anti-complement Factor C1Q Antibodies and Uses Thereof
9 Sep 21
The present invention provides anti-C1q antibodies and methods of using the same.
Arnon Rosenthal, Michael Leviten
Filed: 10 Feb 21
Utility
Humanized Anti-complement Factor C1Q Antibodies and Uses Thereof
22 Apr 21
The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
Arnon Rosenthal, Michael Leviten
Filed: 8 Apr 20
Utility
Anti-complement factor C1Q antibodies and uses thereof
23 Feb 21
The present invention provides anti-C1q antibodies and methods of using the same.
Arnon Rosenthal, Michael Leviten
Filed: 6 Feb 20
Utility
Anti-complement Factor C1Q Fab Fragments and Uses Thereof
7 Oct 20
The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.
Ted Yednock, Sethu Sankaranarayanan, Michael Leviten, Arnon Rosenthal
Filed: 24 Jun 20
Utility
Anti-complement Factor C1Q Antibodies and Uses Thereof
29 Jul 20
The present invention provides anti-C1q antibodies and methods of using the same.
Arnon Rosenthal, Michael Leviten
Filed: 5 Feb 20
Utility
Anti-complement factor C1q Fab fragments and uses thereof
27 Jul 20
The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.
Ted Yednock, Sethu Sankaranarayanan, Michael Leviten, Arnon Rosenthal
Filed: 22 Nov 16
Utility
Compositions and Methods for Treating Brain Injury
6 May 20
The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.
Susanna Rosi, Karen Krukowski, Ted Yednock, Sethu Sankaranarayanan
Filed: 31 Oct 19
Utility
Anti-complement factor C1q antibodies and uses thereof
16 Mar 20
The present invention provides anti-C1q antibodies and methods of using the same.
Arnon Rosenthal, Michael Leviten
Filed: 3 Jan 19
Utility
Humanized Anti-complement Factor C1Q Antibodies and Uses Thereof
16 Oct 19
The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
Arnon Rosenthal, Michael Leviten
Filed: 16 May 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first